High expression of SDF-1 and VEGF is associated with poor prognosis in patients with synovial sarcomas

11Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Stromal cell-derived factor-1 (SDF-1) predicts poor clinical outcomes of certain types of cancer. Furthermore, vascular endothelial growth factor (VEGF) promotes the growth and metastasis of solid tumors. The aim of the present study was to examine the expression of SDF-1 and VEGF in patients with synovial sarcoma and to determine their expression is correlated with unfavorable outcomes. Levels of SDF-1 and VEGF proteins were evaluated in 54 patients with synovial sarcoma using immunohistochemical and immunofluorescence staining. Potential associations between the expression of SDF-1 and VEGF and various clinical parameters were analyzed using Pearson's χ2 test and the Spearman-rho test. Additionally, univariate and multivariate Cox regression analyses were used to identify potential prognostic factors, and the Kaplan-Meier method was used to analyze the overall survival rates of patients. Low SDF-1 and VEGF expression was detected in 20.4% (11/54) and 22.2% (12/54) of patients with synovial sarcoma; moderate expression was detected in 35.2% (19/54) and 37.0% (20/54) of patients and high expression was detected in 44.4% (24 of 54) and 40.7% (22 of 54) of patients, respectively. Levels of SDF-1 and VEGF proteins were significantly associated with histological grade (P<0.05), metastasis (P<0.05) and American Joint Committee on Cancer staging (P<0.05). In addition, levels of SDF-1 and VEGF expression were positively correlated with each other (P<0.001). Univariate analysis also indicated that VEGF expression was associated with shorter overall survival rates in (P<0.05), whereas multivariate analysis demonstrated that SDF-1 expression was associated with shorter patient survival rates (P<0.05). Finally, both SDF-1 and VEGF expression were associated with various characteristics of synovial sarcoma. Therefore, SDF-1 expression may be a potential independent prognostic indicator in patients with synovial sarcomas.

References Powered by Scopus

CXCL12 (SDF-1)/CXCR4 pathway in cancer

1207Citations
N/AReaders
Get full text

CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment

1047Citations
N/AReaders
Get full text

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

649Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Molecular mechanisms underpinning sarcomas and implications for current and future therapy

55Citations
N/AReaders
Get full text

Emerging biomarkers in Multiple Myeloma: A review

48Citations
N/AReaders
Get full text

Next-generation biomarkers in multiple myeloma: Understanding the molecular basis for potential use in diagnosis and prognosis

21Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Feng, Q., Guo, P., Wang, J., Zhang, X., Yang, H. C., & Feng, J. G. (2018). High expression of SDF-1 and VEGF is associated with poor prognosis in patients with synovial sarcomas. Experimental and Therapeutic Medicine, 15(3), 2597–2603. https://doi.org/10.3892/etm.2018.5684

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

60%

Professor / Associate Prof. 1

20%

Researcher 1

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

40%

Biochemistry, Genetics and Molecular Bi... 2

40%

Agricultural and Biological Sciences 1

20%

Save time finding and organizing research with Mendeley

Sign up for free